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ABSTRACT
Background. Hereditary microscopic haematuria often segre-
gates with mutations of COL4A3, COL4A4 or COL4A5 but in
half of families a gene is not identified. We investigated a Cyp-
riot family with autosomal dominant microscopic haematuria
with renal failure and kidney cysts.
Methods.Weused genome-wide linkage analysis, whole exome
sequencing and cosegregation analyses.
Results. We identified a novel frameshift mutation, c.4611_
4612insG:p.T1537fs, in exon 49 of COL4A1. This mutation
predicts truncation of the protein with disruption of the C-
terminal part of the NC1 domain. We confirmed its presence in
20 family members, 17 with confirmed haematuria, 5 of whom
also had stage 4 or 5 chronic kidney disease. Eleven family mem-
bers exhibited kidney cysts (55% of those with the mutation), but
muscle cramps or cerebral aneurysms were not observed and
serum creatine kinase was normal in all individuals tested.
Conclusions. Missense mutations of COL4A1 that encode the
CB3 [IV] segment of the triple helical domain (exons 24 and
25) are associated withHANAC syndrome (hereditary angiopa-
thy, nephropathy, aneurysms and cramps). Missense mutations
of COL4A1 that disrupt the NC1 domain are associated with
antenatal cerebral haemorrhage and porencephaly, but not kid-
ney disease. Our findings extend the spectrum of COL4A1mu-
tations linked with renal disease and demonstrate that the
highly conserved C-terminal part of the NC1 domain of the
α1 chain of type IV collagen is important in the integrity of
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INTRODUCTION
Isolatedmicroscopic haematuria is a significant risk factor for kid-
ney failure in later life [1] and can be the presenting feature of a
number of disorders, which can be monogenic or non-familial.
Since kidney biopsy is seldom performed where there is no evi-
dence of kidney damage (i.e. proteinuria, hypertension or renal
impairment), a firm diagnosis has traditionally only been possible
in patients with more advanced kidney disease. Today, however,
the cause of familial kidney disease may be identified at an early
stage using genetic testing. This can have important implications
for the patient and his/her family because prognosis and risk to
family and offspring depends on the diagnosis [2].
The most common inherited cause of microscopic haema-
turia is thin basement membrane nephropathy (TBMN),
which is characterized by thinning or irregularity of the glom-
erular basement membrane visible on electron microscopy. In
many families a cause is not identified, however, in 40–50%
cases, TBMN is linked with a heterozygous mutation of the
COL4A3, COL4A4 or COL4A5 genes that encode type IV colla-
gen, and the clinical features overlap with the carrier state for
autosomal recessive or X-linked Alport syndrome [3–5]. Most
carriers of a heterozygous COL4A3/4 mutation have an
excellent prognosis; however, 15–20% will develop renal im-
pairment or even end-stage renal disease (ESRD), usually in
later life [4, 6]. Other monogenic causes of kidney disease
that can present with isolated microscopic haematuria include
Alport syndrome, which is either X-linked (caused by hemizy-
gous mutation of COL4A5) or autosomal recessive (caused by
bi-allelic mutation of the COL4A3 or COL4A4 genes); CFHR5
nephropathy (caused by an internal duplication of CFHR5 [7]);
MYH9-associated glomerulopathy (caused by mutations of
MYH9 and also associated with proteinuria, deafness and plate-
let abnormalities [8]); and hereditary angiopathy, nephropathy,
aneurysms and cramps (HANAC) syndrome, which is asso-
ciated with heterozygous mutations in exons 24 and 25 of the
COL4A1 gene [9]. We investigated a family of Turkish Cypriot
origin in which microscopic haematuria and renal impairment
segregated as a dominant trait (Figure 1).
MATERIALS AND METHODS
All research involving human participants was performed with
written informed consent and was approved by the ethics com-
mittee of Lefkosa Burhan Nalbantoğlu State Hospital. All par-
ticipants provided informed consent for their involvement in
the research in accordance with the Declaration of Helsinki
and for publication of the study results. Individuals were geno-
typed on the Linkage IV panel (Illumina, San Diego, CA, USA)
F IGURE 1 : (A) Family tree showing affected individuals participating in the genome-wide linkage study. P denotes proband. Estimated
glomerular filtration rate in mL/min is shown for each individual (where known) and ESRD denotes end-stage renal disease. (B) Electron mi-
crographs of kidney biopsy from individual III-5 showing thin glomerular basement membranes and lamellation and lucencies in the tubular
basement membranes (arrowheads). (C) Genome-wide linkage excluded loci containing genes previously associated with haematuria, except for a
locus on chromosome 13 that contains the COL4A1 gene (inset), LOD score = 3. (D) Sanger sequencing of exon 49 of COL4A1 demonstrated a G
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according to the manufacturers’ instructions. Linkage analysis
was performed using GeneHunter v2.1 [10]. Exome sequencing
was performed by enrichment with the Agilent SureSelect All
Exon array and sequencing using an Illumina Genome Analyz-
er IIx. Reads were aligned to the reference genome (GRCh37)
using Novoalign (Novocraft Technologies, Selangor, Malaysia).
Variants were called using GATK [11] and annotated with An-
novar [12]. Resequencing of COL4A1 exon 49 was performed
using the primers 50-TGCTTGTTGTCCAGCTGAAAT-30
and 50-ACAGGAGGAAAGGCAACCAC-30, amplified by poly-
merase chain reaction at an annealing temperature of 58°C.
Three-dimensional models were generated using Jmol [13],
based on the crystal structure 1li1 from the protein database [14].
Retinol-binding protein (RBP) was assayed as previously
described using a polyclonal in-house sandwich ELISA [15]. Urin-
ary N-acetyl-beta-D-glucosaminidase (NAG) activity was mea-
sured using a kit from PPR Diagnostics (London, UK). Albumin
and creatinine (enzymatic) were measured on an Abbott Architect
(Abbott Diagnostics, Lake Forest, IL, USA).
RESULTS
Clinical information was available for 29 family members, of
whom 19 exhibited >1+ microscopic haematuria on urine dip-
stick testing. Fifteen family members had renal impairment [(es-
timated glomerular filtration rate eGFR) <90 mL/min], three
requiring renal replacement therapy.
Genotype
Genes associated with autosomal dominant thin basement
membrane nephropathy (COL4A3 and COL4A4) were se-
quenced in the proband by amplification of each exon and
Sanger sequencing. This did not reveal any rare or likely patho-
genic variants. A genome-wide linkage study was performed
using DNA from 12 affected family members. This excluded
linkage with loci containing the genes COL4A3, COL4A4,
COL4A5, MYH9 and CFHR5 (LOD < −2 at each locus), but
did demonstrate linkage (LOD = 3) with loci on chromosomes
6 and 13 that include the COL4A1 gene on chromosome 13
(Figure 1C). Whole exome sequencing was performed in the
proband, which identified no likely pathogenic variants in
COL4A3, COL4A4, COL4A5, MYH9 or CFHR5. Across the
whole exome, 688 variants that were both rare (i.e. occur with
an allele frequency of <0.5% in the 1000 genomes database) and
predicted a change in amino acid sequence of a protein (includ-
ing amino acid substitutions, insertions, deletions, splicing,
frameshift or termination mutations) were identified. Of
these, 644 were heterozygous and 270 were novel (i.e. not re-
ported in dbSNP). Two rare variants, both heterozygous, oc-
curred within the linked loci. One variant predicted a
missense mutation p.A101T in TMEM14C (NM_016462) on
chromosome 6. This gene has not previously been associated
with kidney disease and the variant is predicted to be benign,
with SIFT and Polyphen scores of 0.42 and 0.023, respectively.
The other variant was in the COL4A1 gene and encodes a novel
frameshift mutation c.4611_4612insG; p.T1537fs (transcript
NM_00185). This was considered a good candidate for causing
disease since other mutations in this gene are associated with
HANAC syndrome, in which haematuria, kidney cysts and
renal impairment are features.
TheCOL4A1mutation was confirmed by Sanger sequencing
(Figure 1D), and screening across all available samples revealed
its presence in all affected individuals participating in the link-
age study and in a further eight relatives, seven of whom had
one or more of haematuria, cysts or evidence of reduced renal
function (eGFR <90 mL/min). The individual lacking clear evi-
dence of kidney disease was 23 years old at the time of assess-
ment and had trace haematuria on dipstick testing. Eight
offspring of affected familymembers were found not to harbour
the COL4A1 variant, of whom one was found to have dipstick
haematuria on a single occasion, associated with normal renal
function and imaging, and one (designated individual II-6) ex-
hibited renal impairment, haematuria, proteinuria and kidney
cysts (Table 1). We regard these individuals as phenocopies,
which is not an unexpected finding given the high prevalence
of clinical evidence of kidney disease known to be present in
this and other populations [16–18]. Themutation is not present
in any online databases of human genetic variation and was not
detected by sequencing a cohort of 63 unrelated healthy Turk-
ish Cypriot adults.
To determine whether an additional mutation might be seg-
regating in other family members we went on to sequence
COL4A3, COL4A4 and COL4A5 in individual II-2 (who har-
boured the COL4A1 mutation and had developed ESKD) and
individual II-6. No rare or likely pathogenic mutations of
these genes were identified in either of these individuals. We
conclude that the COL4A1 mutation is responsible for the fa-
milial renal disease in this kindred. We went on to examine
whole exome sequencing data from four other families in
which glomerular basement membrane abnormalities and
microscopic haematuria segregated as a dominant trait in the
absence of a COL4A3, COL4A4 or COL4A5 mutation but did
not find any additional likely pathogenic variants in COL4A1.
Table 1. Clinical features in family members with and without the COL4A1
p.T1537fs frameshift mutation
Clinical feature With mutation Without mutation
Haematuria Present 17 2
Absent/trace 2 6
Proteinuria Present 7 1
Absent 12 7
Kidney cysts Present 11 1
Absent 7 4
Creatine kinase Elevated 0 0
Normal 16 6
Retinal vessels Tortuous 0 0
Normal 4 0
Kidney function eGFR > 90 5 7
eGFR 31–90 14 1
eGFR < 30 4 0
ESRD 3 0
Total family members 20 8
Proteinuria: albumin:creatinine ratio >3.0 mg/mmol; kidney cysts: as seen on renal
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Clinical phenotype
Renal failure was unpredictable, with creatinine rising above
the normal range in some affected members after the age of 40
years. End-stage renal failure ranged from 63 to 70 years in three
of nine siblings in the first generation. In those affected, one or
more kidney cysts were detectable by ultrasound from the age of
40 years in 12 family members. Hypertension was variable, but
could be present from 35 years of age. No family members re-
ported a history of muscle cramps or cerebral aneurysms, and
serum creatine kinase was normal in all 22 family members
tested. Some family members had evidence of vascular disease
(summarized in Figure 1A). Hyperuricaemia was not found
and no patient had a history of gout. Brain MRI scanning
and retinal photography in four affected members of the family
revealed no evidence of cerebral or ocular angiopathy.
Little or no proteinuria (albumin:creatinine ratio <3 mg/
mmol) was found until the eGFR was <50 mL/min/1.73 m2.
Urine samples from 15 affected people were also investigated
for tubular proteinuria. Of the 10mutation carriers without mi-
croalbuminuria, 5 had an elevated RBP:creatinine ratio ≥25
mg/mmol (97.5th upper centile <18 mg/mmol creatinine)
and 3 had an elevated NAG:creatinine ratio (normal range
<28 µmol/h/L).
A kidney biopsy was performed in one family member at age
47 years to investigate familial nephropathy and reduced eGFR.
Light microscopic examination was normal with the exception
of minimal global glomerulosclerosis (1 of 25 glomeruli) and
<1% tubular atrophy. Immunostains for type IV collagen
were not performed, but stains for immunoglobulins and com-
plement were negative. Electron microscopy demonstrated
areas of thinning of glomerular basement membranes (down
to 93.5 nm) and subtle lamellation of tubular basement mem-
branes (Figure 1B). Glomerular basement membrane splitting
or irregularity of the outer surface was not observed and the ul-
trastructural appearances were judged to represent thin base-
ment membrane nephropathy rather than Alport syndrome.
DISCUSSION
Type IV collagen is an important constituent of the extracellu-
lar matrix and forms a complex meshwork that provides struc-
tural integrity to basement membranes [19]. Individual type IV
collagen molecules are made up of three alpha chains that form
a heterotrimeric structure that includes a non-collagenous
(NC1) domain at the C-terminus that initiates heterotrimer for-
mation [20], and a long collagenous ‘tail’ interspersed with
non-collagenous interruptions. The collagenous domains of
three alpha chain subunits interweave to form a stiff triple hel-
ical structure and the non-collagenous interruptions likely con-
fer flexibility and allow intermolecular cross-linking, leading to
formation of the macromolecular collagen network [21]. The
NC1 domains of adjacent trimers are themselves covalently
cross-linked by sulfilimine bonds at conserved residues to
form hexamers [22]. The α1.α1.α2 isoform of type IV collagen
is composed of two α1 chains and one α2 chain, encoded by the
genes COL4A1 and COL4A2, respectively, and is very highly
conserved across species, forming an important component
of most basement membranes. This contrasts with the other
naturally occurring type IV collagen isoforms (α3.α4.α5 and
α5.α5.α6) that have a more restricted distribution of expression
and are less broadly conserved across species [21].
Pathogenic mutations of COL4A1 are associated with
neurological, vascular and renal disorders. Previously described
phenotypes cluster into primarily neurological disease, in which
porencephaly (the occurrence of fluid filled cavities in the
brain) and cerebral vasculopathy or haemorrhage cause signifi-
cant neurological damage early in life [23], and HANAC syn-
drome, in which neurological involvement tends to be milder
and haematuria, kidney cysts and occasionally late-onset renal
impairment are features [9]. The mechanisms of pathogenicity
in COL4A1-associated diseases are incompletely understood.
However, it is unlikely that haplo-insufficiency is a major con-
tributor inmost cases: previously described pathogenicmutations
Table 2. The C-terminal NC1 domain of COL4A1 is highly conserved across species
Common name Phylum Latin name Sequence
Mutant allele TPEPMPMSMAPITGGGKHKTIY
Human Chordata Homo sapiens TPEPMPMSMAPITGENIRPFISRCAV…PTPSTLKAGELRTHVSRCQVCMRRT
Chimpanzee Chordata Pan troglodytes TPEPMPMSMAPITGENIRPFISRCAV…PTPSTLKAGELRTHVSRCQVCMRRT
Monkey Chordata Macaca mulatta TPEPMPMSMAPITGDNIRPFISRCAV…PTPSTLKAGELRTHVSRCQVCMRRT
Wolf Chordata Canis lupus TPEPMPMSMAPIAGDNIRPFISRCAV…PTPSTLKAGELRTHVSRCQVCMRRT
Cow Chordata Bos taurus TPEPMPMSMAPITGENIRPFISRCAV…PTPSTLKAGELRTHVSRCQVCMRRT
Mouse Chordata Mus musculus TPEPMPMSMAPISGDNIRPFISRCAV…PTPSTLKAGELRTHVSRCQVCMRRT
Rat Chordata Rattus norvegicus TPEPMPMSMAPISGDNIRPFISRCAV…PTPSTLKAGELRTHVSRCQVCMRRT
Chicken Chordata Gallus gallus TPEPMPMSMAPITGESIRPFISRCSV…PTPSTLKAGDLRSNVSRCQVCMRNT
Zebrafish Chordata Danio rerio TPEPMPMSMAPVTGESIKPFISRCAV…PVPATLKAGSLRTHISRCQVCMKRV
Xenopus Chordata Xenopus tropicalis TPEPMPMSMAPITGDGIKPFISRCTV…PTPSTLKAGDLRTHVSRCQVCMRRTS
Fruit Fly Arthropoda Drosophila melanogaster T-TNAAIPMMPVENIEIRQYISRCVV…PQQQTIKAGERQSHVSRCQVCMKNSS
Roundworm Nematoda Ascaris suum LSTTAPIPMMPVSEGGIEPYISRCAV…PESETLKAGSLRTRVSRCQVCIRSPDVQPYRG
Roundworm Nematoda Caenorhabditis elegans TDEPMTPMMNPVTGTAIRPYISRCAV…PMSQTLKAGGLKDRVSRCQVCLKNR
Pink Hydroid Cnidaria Ectopleura larynx TPEPMPMMMNPVEGRDIEKYVSRCSV…PQSQTLKAGNQRSRISRCQVCMRRR
Freshwater Jellyfish Cnidaria Craspedacusta sowerbyi STEQEPNMMRPSKGIENRDYISRCIV…PVPETIKAGQLRQRVSRCAVCMKNNKANEP
The residues (M93 and K211) that participate in the sulfilimine bond between adjacent heterotrimers are in bold. Approximately 100 residues (denoted by ‘…’) are omitted for clarity. The













C O L 4 A 1 a n d r e n a l d i s e a s e 1911
in humans are almost all missense variants and do not include
early nonsense mutations or heterozygous whole gene deletions;
only a single collagenous-domain frameshift mutation that re-
duced transcript levels has been reported to date [23]. Moreover,
mice heterozygous for a null Col4A1 allele do not display any
detectable phenotype [21].Mutations causingHANACsyndrome
have been reported only in exons 24 and 25 of COL4A1, encod-
ing a region of the protein that contains multiple potential
integrin-binding sites, and it has been suggested that disruption
of normal interaction between type IV collagen and integrins
might be responsible for HANAC syndrome [21, 24]. Thinning
of glomerular basement membranes (in which α3.α4.α5 is the
predominant type IV collagen isoform) is not reported in either
HANAC syndrome or other COL4A1-associated diseases.
Frameshift variants of COL4A1 are exceedingly rare, with
only one example observed (encoding p.P438fs) in >120 000 al-
leles tested in the ExAC project and a single pathogenic allele (p.
G696fs) reported previously in the medical literature [23]. The
p.T1537fs mutation we identified is predicted to result in the
substitution of the 132 C-terminal amino acids of the protein
with the peptide ‘GGGKHKTIY’ followed by a premature ter-
mination codon. Themissing C-terminal domain is highly con-
served across evolution (present even in cnidarian and
nematode species; see Table 2) and includes Lysine 211
(K211), which is essential for the sulfilimine bond cross-linking
adjacent trimers to form hexameric type IV collagen [25]. It
also encodes the part of the protein that interacts with one
(but not both) of the other subunits in a heterotrimer (Figure 2).
F IGURE 2 : (A) The NC1 domain of one α1 chain (white) of a trimeric type IV collagen molecule forms two sulfilimine bonds (yellow) with the
NC1 domain of an α1 chain of the adjacent trimer (violet). Additional alpha chains in each trimer not shown. (B) The NC1 domains of two α1(IV)
chains (white and orange) and one α2(IV) chain (red) interact to form a heterotrimer, viewed face on to the dimerization surface [i.e. perpendicular
to the view shown in (A)]. (C) The truncated protein predicted by the p.T1537fs mutation lacks the C-terminal K211 residue and hence is only able
to form a single sulfilimine bond. (D) Truncation of the protein is predicted to disrupt the normal interaction with one other subunit of a type IV
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One possible mechanism whereby loss of this part of the
NC1 domain could cause disease includes disruption of sulfili-
mine bond(s) by inclusion of one or more defective α1 chain
missing the C-terminal part of its NC1 domain within an α1.
α1.α2 type IV collagen heterotrimer (Supplementary Video
S1). Alternatively, since it is known that α1 type IV chains are
expressed in podocytes and present in glomeruli of healthy
adults [26, 27], it is possible that the defective NC1 domain re-
sulting from thismutation could cause incorrect recognition and
assembly of glomerular type IV collagen heterotrimers [20], per-
haps resulting in incorporation of the mutant α1 subunit in α3.
α4.α5 type IV collagen trimers of glomerular basement mem-
branes. This might explain the observed thinning of glomerular
basement membranes. Our data clearly do not exclude a domin-
ant negative or gain-of-function effect of the mutation mediated
by a mechanism unrelated to trimer formation, such as inter-
action of monomeric mutant protein with type IV collagen via
the non-collagenous interruptions within the alpha chains. The
possibility that the disease mechanism is disruption of basement
membrane formation due to haplo-insufficiency for COL4A1 is
considered less likely for the reasons stated above. A homozy-
gous truncating mutation within the C-terminal NC1 domain
of COL4A4 has previously been reported in association with
autosomal recessive Alport syndrome, but the phenotype of
the obligate carrier parents was not documented in this report
[28], so it is not known whether this similar mutation in a dif-
ferent type IV collagen chain in heterozygosity has similar
phenotypic effects to the mutation described here.
In summary, we present a novel COL4A1 mutation linked
with kidney disease that is predicted to cause loss of a highly
conserved part of the C-terminal NC1 domain of the α1 type
IV collagen chain that is important in interactions within and
between type IV collagen heterotrimers. This demonstrates that
this part of the protein is important in the normal function of
type IV collagen in humans.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford
journals.org.
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